| Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Myovant Sciences Ltd., Akcea Therapeutics, Inc, Verily Life Sciences LLC, Merck KGaA, Valneva SE, IDEAYA Biosciences, Inc., BioNTech SE, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, BioInvent International AB, Sosei Group Corporation, LianBio, and Imcyse S.A. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| BOURLA ALBERT | Chairman & CEO | Nov 09 | Sale | 41.94 | 132,508 | 5,557,386 | 78,273 | Nov 10 05:55 PM | | SUSMAN SALLY | Executive Vice President | Nov 09 | Sale | 41.94 | 43,662 | 1,831,184 | 108,096 | Nov 10 05:55 PM | | PFIZER INC | 10% Owner | Oct 27 | Buy | 10.00 | 1,200,000 | 12,000,000 | 27,349,211 | Oct 29 05:44 PM | | BLAYLOCK RONALD E | Director | Aug 06 | Buy | 38.55 | 13,000 | 501,085 | 13,000 | Aug 10 08:07 AM | | DAMICO JENNIFER B. | SVP & Controller | Jun 05 | Sale | 36.13 | 2,181 | 78,800 | 7,542 | Jun 08 04:29 PM | | Dolsten Mikael | President R&D | May 18 | Sale | 37.78 | 95,353 | 3,602,681 | 174,918 | May 19 05:37 PM | | DAMICO JENNIFER B. | SVP & Controller | Apr 29 | Sale | 38.35 | 2,181 | 83,641 | 9,647 | May 01 03:56 PM | | JOHNSON RADY A | Executive Vice President | Apr 29 | Sale | 38.36 | 13,125 | 503,475 | 63,940 | May 01 03:56 PM | | ROGERS DAWN | Executive Vice President | Apr 29 | Sale | 38.13 | 13,000 | 495,690 | 4,823 | May 01 03:56 PM | | LANKLER DOUGLAS M | Executive Vice President | Apr 29 | Sale | 37.85 | 65,000 | 2,460,372 | 78,276 | May 01 03:56 PM | | PFIZER INC | 10% Owner | Mar 16 | Buy | 16.00 | 312,500 | 5,000,000 | 1,481,719 | Mar 16 07:15 PM |
|
